19.30CHF-9.56%Mkt Cap: 760.65M CHFP/E: 321.67Last update: 2026-06-01
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two se…
Industry Peers
Medical Devices152.01BUSDP/E 24.4
115.59BUSDP/E 34.9
71.08BUSDP/E 20.0
54.41BSEKP/E 101.6
52.05BDKKP/E 22.0
51.03BUSDP/E 47.9
50.55BSEKP/E 21.4
38.34BEURP/E 18.1
Indicators:|
Key Statistics
Company
Market Cap760.65M CHF
Enterprise Value817.19M CHF
Revenue (TTM)146.06M CHF
Gross Profit129.40M CHF
Net Income (TTM)2.55M CHF
Revenue/Share3.800 CHF
Last Price19.30 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees178
CountryCH
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)321.67
P/E (Forward)40.04
PEG—
EV/EBITDA70.94
EV/Revenue5.59
P/S5.76
P/B12.67
EPS (TTM)0.06
EPS (Forward)0.53
52W Range
18.704% of range34.20
52W High34.20 CHF
52W Low18.70 CHF
Profitability
Gross Margin88.60%
Oper. Margin6.59%
EBITDA Margin7.89%
Profit Margin1.75%
ROE3.02%
ROA1.91%
Growth
Revenue Growth66.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-455.00K CHF
CapEx (TTM)2.44M CHF
FCF Margin-2.69%
FCF Yield-0.52%
Net Debt-18.38M CHF
Net Debt/EBITDA-1.60
Balance Sheet
Debt/Equity0.02
Current Ratio1.96
Quick Ratio1.42
Book Value/Sh1.684 CHF
Cash/Share0.5050 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 8, 2020
Splits
Last Split1:100
Split DateJun 23, 2016
Analyst Consensus
Rating—
Target (Mean)35.40 CHF
Target Range32.80 CHF – 38.00 CHF
# Analysts2
Ownership
Shares Out.39.41M
Float28.87M
Insiders28.93%
Institutions21.55%
Technical
SMA 5022.20 (-13.1%)
SMA 20025.96 (-25.7%)
Beta0.70
S&P 52W Chg27.70%
Avg Vol (30d)210.88K
Avg Vol (10d)168.17K
Technical Indicators
RSI (14)47.9
MACD-0.2582
MACD Signal-0.4931
MACD Hist.+0.2349
BB Upper22.47 CHF
BB Middle20.76 CHF
BB Lower19.06 CHF
BB Width16.44%
ATR (14)1.064 CHF
Vol Ratio (20d)0.72x